Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia

Ticker(s): BMY

Who's the expert?

Institution: University of Indiana

Professor of Psychiatry at the University of Indiana
Manages approximately 50 schizophrenia patients each month.
Research focus on schizophrenia; author on Emergent trial published in NEJM.

Interview Goal

On this call we will be digging in to the the results from the EMERGENT-3 and EMERGENT-4 studies and discussing the potential of KarXT in adults as both a monotherapy and adjunctive therapy for the treatment of schizophrenia. Also looking at the results presented at the 2024 Annual Congress of the Schizophrenia International Research Society

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.